Anzeige
Meldung des Tages: Lettland-Defence-Zertifikat! Diese Aktie öffnet die Tür zu bis zu 3 Mio. € Finanzierung

Urogen Pharma Aktie News

Aktie
WKN:  A2DTCV ISIN:  IL0011407140 US-Symbol:  URGN Branche:  Biotechnologie Land:  USA
21,07 $
-0,72 $
-3,30%
17,884 € 20.02.26
Depot/Watchlist
Marktkapitalisierung *
902,08 Mio. €
Streubesitz
-
KGV
-3,94
Index-Zuordnung
-

Urogen Pharma News

02.07.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGN
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGN PR ...
30.06.25 - PR Newswire
URGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
URGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action ...
27.06.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN PR Newswire
22.06.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN PR Newswire
17.06.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN PR Newswire
16.06.25 - PR Newswire
URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm
URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
16.06.25 - PR Newswire
UroGen Pharma Ltd. Class Action: The Gross Law Firm Reminds UroGen Pharma Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 28, 2025 - URGN
UroGen Pharma Ltd. Class Action: The Gross Law Firm Reminds UroGen Pharma Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 28, 2025 - ...
15.06.25 - PR Newswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen PR Newswire
13.06.25 - PR Newswire
UroGen Pharma Ltd. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 28, 2025 to Discuss Your Rights - URGN
UroGen Pharma Ltd. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 28, 2025 to Discuss Your Rights - URGN PR Newswire
12.06.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN PR Newswire
12.06.25 - PR Newswire
Shareholders that lost money on UroGen Pharma Ltd.(URGN) should contact The Gross Law Firm about pending Class Action - URGN
Shareholders that lost money on UroGen Pharma Ltd.(URGN) should contact The Gross Law Firm about pending Class Action - URGN PR Newswire
11.06.25 - PR Newswire
URGN INVESTOR NOTICE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
URGN INVESTOR NOTICE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit PR Newswire
10.06.25 - PR Newswire
URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit
URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit PR Newswire
10.06.25 - PR Newswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen PR Newswire
10.06.25 - PR Newswire
Shareholders that lost money on UroGen Pharma Ltd.(URGN) should contact Levi & Korsinsky about pending Class Action - URGN
Shareholders that lost money on UroGen Pharma Ltd.(URGN) should contact Levi & Korsinsky about pending Class Action - URGN PR Newswire
09.06.25 - PR Newswire
UroGen Pharma Ltd. (URGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
UroGen Pharma Ltd. (URGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire
09.06.25 - PR Newswire
URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm
URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
09.06.25 - PR Newswire
Class Action Filed Against UroGen Pharma Ltd. (URGN) - July 28, 2025 Deadline to Join - Contact The Gross Law Firm
Class Action Filed Against UroGen Pharma Ltd. (URGN) - July 28, 2025 Deadline to Join - Contact The Gross Law Firm PR Newswire
07.06.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN PR Newswire
06.06.25 - PR Newswire
URGN INVESTOR DEADLINE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
URGN INVESTOR DEADLINE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit PR Newswire

Newssuche

Videos

newspaper
18.02.26 -2,76%
Technical Trading: Chance mit 82 Prozent Treffern
Rohöl Long Typ: Turbo Open End WKN: VH65XQ Hebel:6 Laufzeit: OpenEnd Einstieg: Market ... Mehr »
Anzeige

Aktie im Fokus

Breaking News
DiagnosTear Technologies Inc
0,268 €
+5,51%
DiagnosTear Technologies Inc Chart
TeaRx™ erobert Großbritannien im Sturm?!
Mehr zur Aktie »